/** Title: Epigral Q4 FY26: Utilisation-led rebound, with big capacity additions lined up */

Epigral Q4 FY26: Utilisation-led rebound, with big capacity additions lined up

Epigral ended FY2026 on a stronger note, with Q4 delivering its highest ever quarterly revenue of INR 736 crore. The company reported a 22% quarter-on-quarter rise in revenue and a sharp recovery in profitability, as plants returned to normal operations after scheduled maintenance in Q3. EBITDA rose 64% sequentially to INR 169 crore and EBITDA margin improved to 23% from 17% in the previous quarter. PAT increased to INR 82 crore from INR 39 crore, with PAT margin at 11%.

The full year picture was softer. FY2026 revenue was largely flat at INR 2,542 crore, down 1% year-on-year, as total sales volume fell 4%. EBITDA declined to INR 567 crore from INR 711 crore in FY2025, and margin slipped to 22%. Reported PAT was INR 333 crore, but management clarified that this includes a one-time deferred tax liability reduction of INR 81 crore. Excluding this benefit, PAT would have been INR 252 crore.

Q4 recovery: volumes, utilisation and a more favourable mix

Management framed Q4 as a recovery quarter on three levers. First was volume. The company reported 15% quarter-on-quarter volume growth and indicated overall plant utilisation above 80%. Second was a normalisation in inventory costs and raw material trends compared to Q3, which supported the margin rebound. Third was mix. Derivatives and specialty contributed 54% of Q4 revenue, up from 52% in Q3.

At a segment level, the company’s revenue mix has been steadily shifting over time. In FY2022, chlor-alkali accounted for 75% of revenue. By FY2026, derivatives and specialty were already 52% of revenue. Management sees this as the core de-risking lever in a volatile chemical cycle.

FY2026: maintenance downtime, monsoon disruption, and margin compression

FY2026 was impacted by a combination of operational and market factors. On the operational side, the company carried out major maintenance, described on the concall as a once-in-eight-years activity, which constrained utilisation in the first half. On the demand side, management pointed to an extended monsoon and muted CPVC demand in the first half, along with volatility in PVC prices.

These factors translated into lower volumes and weaker profitability. EBITDA declined 20% to INR 567 crore and PAT fell 7% to INR 333 crore. Management explicitly highlighted that ROCE declined to 16% from 25% in FY2025 due to lower utilisation, sizeable capital work in progress, and profitability pressure from higher raw material prices.

Net leverage remained moderate even during the capex cycle. Net debt to EBITDA was 0.9x as of 31 March 2026, compared with 0.7x a year earlier. On the concall, management stated net debt was INR 508 crore and the company generated around INR 436 crore from operations in FY2026, alongside capex spend of INR 394 crore.

The growth plan: doubling CPVC and ECH, and lifting renewable power share

Epigral’s near-term strategy is tied to three capex tracks.

The biggest is CPVC resin expansion. The company plans to add 75,000 TPA, taking total CPVC resin capacity to 150,000 TPA. The investor presentation states expected commissioning in H1 FY27, while a capex update table lists Q2 FY27. Management’s stated rationale is strong expected domestic CPVC demand growth of around 12% to 13% CAGR, import substitution, and higher in-house chlorine consumption.

The second is epichlorohydrin expansion. An additional 50,000 TPA is expected to take total ECH capacity to 100,000 TPA. The deck cites high double-digit domestic demand growth and deeper integration through captive use of chlorine, hydrogen, and caustic soda.

The third is energy. The company is adding 19.80 MW under a wind-solar hybrid power project, taking total capacity to 38.14 MW, expected to be commissioned in Q2 FY27. Management stated that renewables contribute around 8% to 9% of current power consumption, and could rise to around 15% once the additional capacity ramps up.

A parallel track is the chlorotoluenes value chain, which was commissioned earlier. The capex update table lists commissioning in March 2025. On the concall, management said customer approvals and testing are largely complete, volumes are rising month-on-month, and FY27 should see meaningful contribution, with optimum utilisation targeted in FY28.

What management expects next: volume growth, but macro uncertainty remains

Management avoided giving explicit revenue or margin guidance, but provided two directional anchors.

First, volume growth. Management guided for around 10% to 12% volume growth in FY27, subject to macro conditions.

Second, the macro risk. The concall focused heavily on the West Asia conflict and its impact on supply chains, shipping lines, raw material availability, and pricing. Management said even if the conflict cools, it may take four to five months for markets to stabilise. It also provided an ECU update for caustic soda. Q4 ended with an ECU around INR 30,000, while the current ECU was indicated around INR 37,000, following a 30% to 35% price increase during the escalation.

The management commentary suggests Q1 FY27 could reflect a greater impact of elevated pricing, since Q4 had limited benefit due to prior order booking cycles. At the same time, it acknowledged that higher input costs can dampen volumes in certain products, even as other parts of the product basket remain resilient.

Takeaways

Epigral’s Q4 performance largely reflected a return to normal operations, with utilisation recovery and improved inventory economics translating into higher profitability. FY2026 was weaker because of planned downtime and demand disruptions, but the balance sheet stayed relatively conservative with net debt to EBITDA at 0.9x.

The next phase is execution-driven. If CPVC and ECH expansions are commissioned on schedule in FY27 and ramped through FY28, the company’s stated goal of shifting revenue mix towards derivatives and specialty becomes more plausible. The main swing factor is macro volatility, especially raw materials and logistics influenced by geopolitics, which management repeatedly flagged as uncertain.